Value of preoperative inflammatory biomarkers in predicting long-term prognosis of lung adenocarcinoma patients after microwave ablation
LIU Mengjie1, FU Yili2, WANG Jing2, CUI Songping2, ZHAO Qing2, CHANG Xiner1
1. Department of Respiratory and Critical Care Medicine; 2. Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
Abstract：Objective To explore the value of preoperative inflammatory biomarkers in predicting the long-term prognosis of patients with lung adenocarcinoma after Microwave Ablation (MWA). Methods Patients with early-stage lung adenocarcinoma patients who underwent MWA at Beijing Chao-Yang Hospital from January 2012 to June 2021 were included. The area under the curve (AUC) of the receiver's operating characteristic (ROC) curve was used to assess the predictive value of inflammatory biomarkers. Multivariate Cox risk analysis was used to explore the effectiveness of inflammatory biomarkers in predicting outcomes. Results A total of 143 patients were enrolled. The AUC of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune inflammation index (SII), and systemic inflammation response index (SIRI) for overall survival (OS) were 0.787, 0.731, 0.725, 0.780, and 0.802, respectively. The AUC of NLR, PLR, MLR, SII, and SIRI for disease-free survival (DFS) were 0.700, 0.623, 0.556, 0.718, and 0.668, respectively. Cox risk analysis showed that high SII was independently associated with low OS (OR=1.066, P=0.019) and low DFS (OR=1.068, P=0.016). Kaplan-Meier survival analysis revealed that patients with high preoperative SII had significantly worse prognosis (P<0.001). Conclusions Preoperative SII is an effective marker in predicting the long-term prognosis of early-stage lung adenocarcinoma patients after MWA. Other risk factors also include tumor size, degree of differentiation and smoking status.
刘梦捷, 傅毅立, 汪京, 崔松平, 赵晴, 常鑫儿. 术前炎症生物标志物对预测肺腺癌患者微波消融术后长期预后的价值[J]. 武警医学, 2025, 36(3): 208-212.
LIU Mengjie, FU Yili, WANG Jing, CUI Songping, ZHAO Qing, CHANG Xiner. Value of preoperative inflammatory biomarkers in predicting long-term prognosis of lung adenocarcinoma patients after microwave ablation. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(3): 208-212.
Chan M V, Huo Y R, Cao C, et al. Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer (NSCLC): a systematic review and meta-analysis[J]. Eur Radiol, 2021,31(7):5421-5433.
[2]
Lu Y, Lu C, Xu D, et al. Computed tomography-guided percutaneous radiofrequency ablation in older adults with early-stage peripheral lung cancer: a retrospective cohort study[J]. Cancer Control, 2022,29: 10732748211070702.
[3]
Vogl T J, Naguib N N, Gruber-Rouh T, et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases[J]. Radiology, 2011,261(2):643-651.
[4]
Kim H, Park B J, Kim Y S, et al. Radiofrequency ablation for multiple primary lung cancer: A single center experience[J].J Thorac Dis, 2019,11(4):1555-1563.
Singh R, Mishra MK, Aggarwal H. Inflammation, Immunity, and Cancer[J]. Mediators Inflamm, 2017;2017:6027305.
[7]
Abolhassani H, Wang Y, Hammarström L, et al. Hallmarks of cancers: primary antibody deficiency versus other inborn errors of immunity[J]. Front Immunol, 2021,17(12):720025.
[8]
Cao B, Liu M, Wang L, et al. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer[J]. Nat Commun, 2022,13(1):6203.
[9]
Yin L, Li X Y, Zhu L L, et al. Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy[J]. Front Immunol, 2022,9(5):13:965120.
[10]
Wang J, Li H, Xu R, et al. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery[J]. BMC Pulm Med, 2022,22(1):104.
Feng Y, Zhang N, Wang S, et al. Systemic inflammation response index is a predictor of poor survival in locally advanced nasopharyngeal carcinoma: a propensity score matching study[J]. Front Oncol, 2020,(10):575417.
[13]
Zhang N, Liu H, Yang J,et al. Development and validation of a nomogram based on multiple preoperative immunoinflammatory indexes for survival prediction in patients with stage IA-IB endometrial cancer[J]. Am J Transl Res,2023,15(10):6286-6298.
[14]
Wu M, Wu S, Chen Y,et al. Immune activation effects at different irradiated sites and optimal timing of radioimmunotherapy in patients with extensive-stage small cell lung cancer: a real-world analysis[J]. Biol Proced Online, 2023,25(1):24.
[15]
Tacconi F, Mangiameli G, Voulaz E, et al. Blood-derived systemic inflammation markers and risk of nodal failure in stage ia non-small cell lung cancer: a multicentric study[J]. J Clin Med,2023,12(15):4912.
[16]
Wang Y, Li Y, Chen P, et al. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis[J]. Ann Transl Med, 2019,7(18):433.
[17]
Huang W, Luo J, Wen J, et al. The Relationship between systemic immune inflammatory index and prognosis of patients with non-small cell lung cancer: a meta-analysis and systematic review[J]. Front Surg,2022,(9): 898304.
[18]
Hu B, Yang X R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014,20(23):6212-6122.
[19]
Jomrich G, Gruber E S, Winkler D, et al. Systemic immune-inflammation index (sii) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg, 2020,24(3):610-618.
[20]
Chen J H, Zhai E T, Yuan Y J, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer[J]. World J Gastroenterol, 2017,23(34):6261-6272.
[21]
Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019,33(8):e22964.
[22]
Li Z, Xu W, Gu T, et al. Tumor size, but not consolidation-to-tumor ratio, is an independent prognostic factor for part-solid clinical T1 non-small cell lung cancer[J]. Thorac Cancer, 2023,14(6):602-611.
Lee J M, Jin G Y, Goldberg S N, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report[J]. Radiology, 2004,23(1):125-134.
[25]
Ambrogi M C, Fanucchi O, Cioni R, et al. Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study[J]. J Thorac Oncol, 2011, 6(12):2044-2051.
[26]
Yoon H Y, Park H S, Cho M S, et al. Spontaneous remission of advanced progressive poorly differentiated non-small cell lung cancer: a case report and review of literature[J]. BMC Pulm Med, 2019,19(1):210.
[27]
Sun Z, Aubry M C, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases[J]. J Thorac Cardiovasc Surg, 2006,131(5):1014-1020.
[28]
Gu T, Ren J, Hu Z, et al. A predictive model based on liquid biopsy for non-small cell lung cancer to assess patient's prognosis: Development and application[J]. Tissue Cell, 2022 ,77:101854.
[29]
Guo N L, Tosun K, Horn K. Impact and interactions between smoking and traditional prognostic factors in lung cancer progression[J]. Lung Cancer,2009,66(3):386-392.
[30]
Avci N, Hayar M, Altmisdortoglu O, et al. Smoking habits are an independent prognostic factor in patients with lung cancer[J]. Clin Respir J,2017 ,11(5):579-584.
[31]
Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC[J]. J Thorac Oncol, 2010 ,5(5):620-630.
[32]
Huang L, Shi Y. Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis[J]. Thorac Cancer, 2020 m11(11):3252-3259.
2025, Vol. 36 
